Reviva Pharmaceuticals Holdings Inc. (NASDAQ:RVPH)’s traded shares stood at 0.31 million during the last session, with the company’s beta value hitting -0.09. At the close of trading, the stock’s price was $0.97, to imply an increase of 7.70% or $0.07 in intraday trading. The RVPH share’s 52-week high remains $6.80, putting it -601.03% down since that peak but still an impressive 38.14% since price per share fell to its 52-week low of $0.60. The company has a valuation of $28.90M, with an average of 1.21 million shares in intraday trading volume over the past 10 days and average of 416.09K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Reviva Pharmaceuticals Holdings Inc. (RVPH), translating to a mean rating of 1.50. Of 1 analyst(s) looking at the stock, 0 analyst(s) give RVPH a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.28.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Reviva Pharmaceuticals Holdings Inc. (NASDAQ:RVPH) trade information
After registering a 7.70% upside in the last session, Reviva Pharmaceuticals Holdings Inc. (RVPH) has traded red over the past five days. The 5-day price performance for the stock is 50.50%, and -23.08% over 30 days. With these gigs, the year-to-date price performance is -81.18%. Short interest in Reviva Pharmaceuticals Holdings Inc. (NASDAQ:RVPH) saw shorts transact 4.45 million shares and set a 14.6 days time to cover.
Reviva Pharmaceuticals Holdings Inc. (RVPH) estimates and forecasts
Looking at statistics comparing Reviva Pharmaceuticals Holdings Inc. share performance against respective industry, we note that the company has outperformed competitors. Reviva Pharmaceuticals Holdings Inc. (RVPH) shares are -77.82% down over the last 6 months, with its year-to-date growth rate higher than industry average at 40.61% against 19.70%. Revenue is forecast to grow 36.40% this quarter before jumping 20.00% for the next one.
RVPH Dividends
Reviva Pharmaceuticals Holdings Inc. has its next earnings report out on 2024-Nov-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Reviva Pharmaceuticals Holdings Inc. (NASDAQ:RVPH)’s Major holders
Reviva Pharmaceuticals Holdings Inc. insiders hold 16.58% of total outstanding shares, with institutional holders owning 24.03% of the shares at 28.81% float percentage. In total, 24.03% institutions holds shares in the company, led by WOODLINE PARTNERS LP. As of 2024-06-30, the company held over 1.59 million shares (or 6.6273% of shares), all amounting to roughly $2.04 million.
The next major institution holding the largest number of shares is MILLENNIUM MANAGEMENT LLC with 1.24 million shares, or about 5.1656% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $1.59 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Reviva Pharmaceuticals Holdings Inc. (RVPH) shares. Going by data provided on Mar 31, 2024 , Vanguard Total Stock Market Index Fund holds roughly 700.44 shares. This is just over 2.35% of the total shares, with a market valuation of $0.68 million. Data from the same date shows that the other fund manager holds a little less at 279.27, or 0.94% of the shares, all valued at about 0.27 million.
